Better and more affordable treatments for autoimmune diseases

Stuart SchlossmanGeneral

(December 13, 2011)
(Medical Xpress) — From Addison’s disease to Rheumatoid Arthritis, Crohn’s disease to Multiple Sclerosis — the list of crippling autoimmune diseases is long and they affect millions of people world-wide. But supplies of the plasma-based treatment that has become a lifeline for sufferers are limited because it is very expensive and difficult to make.


Many immune-deficient patients are dependent on the clinically approved plasma protein replacement therapy — Intravenous Immunoglobulin Therapy (IVIG). Seventy per cent of the global supply of IVIG is used to treat autoimmune disease, but this treatment requires thousands of carefully screened donors.

Now experts in the School of Biology at The University of Nottingham have developed a synthetic replacement for the effective part of the antibody — the Fc — which is responsible for dampening the inflammation seen in autoimmune disease. The results of this research, which could lead to a new form of treatment for autoimmune disease, have been published online in the new academic journal Scientific Reports.
Professor Richard Pleass and Professor Mike Doenhoff led the study by the Institute of Genetics in the School of Biology at The University of Nottingham. Professor Pleass said: “The trick that makes these reagents better at potentially curing autoimmune disease is the fact that they are polymeric – made of a repeating unit of proteins.  This makes them much better at suppressing the pro-inflammatory processes involved in causing autoimmune disease than the single molecule antibodies contained in IVIG.”
Existing IVIG products are used every day with great efficacy in treating such as Guillain-Barre syndrome and immune thrombocytopenic purpura (ITP) in children. However, to produce IVIG every single one of the 3,000 donors has to be screened for infectious disease and degenerative disorders and the process of purifying antibodies from these individuals is very costly. To be effective IVIG also needs to be used in high doses since only one per cent of the injected IVIG is suppressive in people. This is because these antibodies are single proteins which have only a mild effect on the inhibitory receptors responsible for switching off inflammation.
The newly described process of synthesising Fc should help overcome these problems.
The research was carried out by Professor Pleass, Professor Doenhoff and their students in collaboration with the Chinese Academy of Sciences, Shanghai Jiao Tong University, the University of Oslo and the University of Alexandria.
More information: A copy of their paper can be found at:http://www.nature. … ep00124.html
Article source; MEDICAL-EXPRESS


..Comments for each blog posting are always appreciated. 

     Please use the link found below, to leave comments.. All comments are moderated to reduce SPAM and bad language
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
 – Click to: REGISTER – For our MS weekly e-Newsletter

Providing You with ‘MS Views and News’, IS What We Do”   ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 

Disclaimer:  ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews